Effectiveness of dorzolamide-timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: The COSOPT first-line study

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 5, 2010, Pages 503-511

  Crichton, Andrew C S ^a   Harasymowycz, Paul ^b   Hutnik, Cindy M L ^c   Behki, Rama ^d   Boucher, Serge ^e   Ibrahim, Fahim ^f   Rifkind, Aaron W ^f   Solomon, Leon ^g   Liao, Chuanhong ^h   Bastien, Natacha R ⁱ   Sampalis, John S ^j,k  

^a UNIVERSITY OF CALGARY   (Canada)

^b Rehabilitation Institute of Montreal   (Canada)

^c Ivey Eye Institute   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Clinique d'Ophtalmologie du Haut Richelieu   (Canada)

^f Private Practice   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^j INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^k MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EYE IRRITATION; EYE PAIN; EYELID EDEMA; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; SIDE EFFECT; TINNITUS; TREATMENT OUTCOME;

AGED; DRUG COMBINATIONS; EYE; FEMALE; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 77957954012     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0032     Document Type: Article

References (37)

1. Sommer, A., Tielsch, J.M., Katz, J., Quigley, H.A., Gottsch, J.D., Javitt, J., and Singh, K. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. 109:1090-1095, 1991.
2. National Eye Health Program/National Institutes of Health (http://www.nei.nih.gov).
3. Bulletin of the World Health Organization. Genebra November 2004; vol.82 no.11.
4. Scherer, W.J. A retrospective review of non-responders to latanoprost. J. Ocul. Pharmacol. Ther. 18:287-291, 2002.
5. Camras, C.B., and Hedman, K. U.S. Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J. Glaucoma. 12:466-469, 2003.
6. Stewart, W.C., Pfeiffer, N., and Mathis, H.M. Meta-analysis of articles evaluating routine intraocular pressure control in monotherapy in the United States and Germany. Eur. J. Ophthalmol. 19:769-775, 2009.
7. Konstas, A.G., Kozobolis, V.P., Tersis, I., Leech, J., and Stewart, W.C. The efficacy and safety of the timolol/dorzolamide fixed combination vs. latanoprost in exfoliation glaucoma. Eye 17:41-46, 2003.
8. Day, D.G., Sharpe, E.D., Beischel, C.J., Jenkins, J.N., Stewart, J.A., and Stewart, W.C. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur. J. Ophthalmol. 15:336-342, 2005.
9. Ozturk, F., Ermis, S.S., and Inan, U.U. Comparison of the ocular hypotensive effects of bimatoprost and timololdorzolamide combination in patients with elevated intraocular pressure: a 6-month study. Acta. Ophthalmol. Scand. 85:80-83, 2007.
10. Caça, I., Simsek, H., Unlü , K., Ari, S., and Keklikçi, U. A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma. Ann. Ophthalmol. 38:111-115, 2006.
11. Coleman, A.L., Lerner, F., Bernstein, P., and Whitcup, S.M. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 110:2362-2368, 2003.
12. Stjernschantz, J.W., Albert, D.M., Hu, D.N., Drago, F., and Wistrand, P.J. Mechanism and clinical significance of prostaglandin- induced iris pigmentation. Surv. Ophthalmol. 47 Suppl 1:S162-S175, 2002.
13. Wistrand, P.J., Stjernschantz, J., and Olsson, K. The incidence and time-course of latanoprost-induced iridial pigmentationas a function of eye color. Surv. Ophthalmol. 41 Suppl 2:S129-S138, 1997.
14. Chiba, T., Kashiwagi, K., Chiba, N., Ishijima, K., Furuichi, M., Kogure, S., Abe, K., and Tsukahara, S. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br. J. Ophthalmol. 87:956-959, 2003.
15. Chou, S.Y., Chou, C.K., Kuang, T.M., and Hsu, W.M. Incidence and severity of iris pigmentation on latanoprosttreated glaucoma eyes. Eye 19:784-787, 2005.
16. Leske, M.C., Heijl, A., Hussein, M., Bengtsson, B., Hyman, L., and Komaroff, E. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121:48-56, 2003. (Pubitemid 36401765)
17. Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, J.P., Parrish, R.K., 2nd, Wilson, M.R., and Gordon, M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713, 2002.
18. Heijl, A., Leske, M.C., Bengtsson, B., Hyman, L., Bengtsson, B., and Hussein, M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120:1268-1279, 2002.
19. Leskea, M.C., Heijl, A., Hyman, L., Bengtsson, B., and Komaroff, E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr. Opin. Ophthalmol. 15:102-106, 2004.
20. Harris, A., Arend, O., Kagemann, L., Garrett, M., Chung, H.S., and Martin, B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J. Ocul. Pharmacol. Ther. 15:189-197, 1999.
21. Lippa, E.A., Carlson, L.E., Ehinger, B., Eriksson, L.O., Finnström, K., Holmin, C., Nilsson, S.E., Nyman, K., Raitta, C., Ringvold, A., et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 110:495-499, 1992.
22. Whitson, J.T., Henry, C., Hughes, B., Lee, D.A., Terry, S., and Fechtner, R.D. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J. Glaucoma 13:168-173, 2004.
23. Hutzelmann, J., Owens, S., Shedden, A., Adamsons, I., and Vargas, E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br. J. Ophthalmol. 82:1249-1253, 1998.
24. Boyle, J.E., Ghosh, K., Gieser, D.K., and Adamsons, I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 105:1945-1951, 1998.
25. Clineschmidt, C.M., Williams, R.D., Snyder, E., and Adamsons, I.A. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamidetimolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 105:1952-1959, 1998.
26. Choudhri, S., Wand, M., and Shields, M.B. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am. J. Ophthalmol. 130:832-833, 2000.
27. Harris, A., Jonescu-Cuypers, C.P., Kagemann, L., Nowacki, E.A., Garzozi, H., Cole, C., and Martin, B. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 132:490-495, 2001.
28. Francis, B.A., Du, L.T., Berke, S., Ehrenhaus, M., and Minckler, D.S. Cosopt Study Group. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol-a randomized controlled trial and a replacement study. J. Clin. Pharm. Ther. 29:375-380, 2004.
29. Yeh, J., Kravitz, D., and Francis, B. Rational use of the fixed combination of dorzolamide timolol in the management of raised intraocular pressure and glaucoma. Clin. Ophthalmol. 2:389-399, 2008.
30. Henderer, J.D., Wilson, R.P., Moster, M.R., Myers, J., Schmidt, C., Fontanarosa, J., and Steinmann, W.C. Timolol/ dorzolamide combination therapy as initial treatment for intraocular pressure over 30mm Hg. J. Glaucoma 14:267-270, 2005.
31. Pajic, B. Conductors of the Swiss COSOPT Survey (CSCS). Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices. Curr. Med. Res. Opin. 19:95-101, 2003.
32. Damji, K.F., Behki, R., and Wang, L. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can. J. Ophthalmol. 38:189-197, 2003.
33. Rolle, T., Tofani, F., Brogliatti, B., and Grignolo, F.M. The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flowin primary open-angle glaucoma patients. Eye 22:1172-1179, 2008.
34. Fechtner, R.D., Airaksinen, P.J., Getson, A.J., Lines, C.R., and Adamsons, I.A. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand. 82:42-48, 2004.
35. Fechtner, R.D., McCarroll, K.A., Lines, C.R., and Adamsons, I.A. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J. Ocul. Pharmacol. Ther. 21:242-249, 2005.
36. Konstas, A.G., Kozobolis, V.P., Tsironi, S., Makridaki, I., Efremova, R., and Stewart, W.C. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology 115:99-103, 2008.
37. Strohmaier, K., Snyder, E., DuBiner, H., and Adamsons, I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 106:1-9, 1999.